Literature DB >> 13713829

Effect of Vincaleukoblastine on metastatic choriocarcinoma and related trophoblastic tumors in women.

R HERTZ, M B LIPSETT, R H MOY.   

Abstract

Entities:  

Keywords:  ALKALOIDS/therapy; ANTINEOPLASTIC AGENTS/therapy; CHORIOCARCINOMA/therapy; TROPHOBLASTIC TUMOR/therapy

Mesh:

Substances:

Year:  1960        PMID: 13713829

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  12 in total

1.  THE CHEMOTHERAPY OF MALIGNANT DISEASE--PRACTICAL AND EXPERIMENTAL CONSIDERATIONS.

Authors:  J MATTHIAS
Journal:  Postgrad Med J       Date:  1965-05       Impact factor: 2.401

2.  Clinical experience with vinblastine sulfate.

Authors:  O H WARWICK; R E ALISON; J M DARTE
Journal:  Can Med Assoc J       Date:  1961-09-02       Impact factor: 8.262

3.  Vincaleukoblastine in the treatment of malignant disease.

Authors:  D M WHITELAW; J M TEASDALE
Journal:  Can Med Assoc J       Date:  1961-09-02       Impact factor: 8.262

4.  Immunotherapy of a patient with choriocarcinoma.

Authors:  B CINADER; M A HAYLEY; W D RIDER; O H WARWICK
Journal:  Can Med Assoc J       Date:  1961-02-11       Impact factor: 8.262

5.  Current concepts of cancer chemotherapy.

Authors:  R J PAPAC; D A WOOD
Journal:  Calif Med       Date:  1962-06

6.  The Positive Signs of Neurosis.

Authors:  D B Guest
Journal:  Can Med Assoc J       Date:  1961-09-02       Impact factor: 8.262

7.  Chemotherapy in Malignant Disease: The Present Position.

Authors:  A E Buckle
Journal:  Postgrad Med J       Date:  1961-06       Impact factor: 2.401

8.  Side-effects of Vinca alkaloids.

Authors:  W G Bradley
Journal:  Br Med J       Date:  1968-07-06

9.  [Long term treatment of advanced lymphogranulomatosis with vinblastine sulfate].

Authors:  E Schulz; W Jüngling; K Hausmann
Journal:  Klin Wochenschr       Date:  1969-02-15

10.  O. Harold Warwick: Canada's first medical oncologist.

Authors:  D H Cowan
Journal:  Curr Oncol       Date:  2011-06       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.